Skip to main content

Primary Dysmenorrhea

6
Pipeline Programs
8
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
5
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
low level light therapyPhase 41 trial
Active Trials
NCT03953716Unknown480Est. Jun 2020
EMS
EMSBrazil - Hortolândia
3 programs
2
CDE100 associationPhase 31 trial
DEH113Phase 31 trial
DEH113N/A1 trial
Active Trials
NCT06555549Not Yet Recruiting60Est. Feb 2026
NCT05640232Recruiting238Est. Jan 2027
NCT06268054Not Yet Recruiting78Est. Sep 2027
Bayer
BayerLEVERKUSEN, Germany
2 programs
2
Drug: YAZ flexPhase 31 trial
Estradiol valerate, DienogestPhase 31 trial
Active Trials
NCT00569244Completed223Est. Dec 2009
NCT00909857Completed507Est. Nov 2010
Daewon Pharma
Daewon PharmaKorea - Hwaseong
1 program
1
Pelubiprofen 45mgPhase 31 trial
Active Trials
NCT04541134Unknown120Est. Aug 2021
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Quantitative Sensory TestingN/A1 trial
Active Trials
NCT04685343Completed164Est. Dec 2025
MTI
MTIUT - Salt Lake City
1 program
shock wave therapyN/A1 trial
Active Trials
NCT04662814Completed50Est. Jan 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
UNION therapeuticslow level light therapy
EMSCDE100 association
EMSDEH113
Daewon PharmaPelubiprofen 45mg
BayerEstradiol valerate, Dienogest
BayerDrug: YAZ flex
EMSDEH113
Human BioSciencesQuantitative Sensory Testing
MTIshock wave therapy

Clinical Trials (9)

Total enrollment: 1,920 patients across 9 trials

NCT03953716UNION therapeuticslow level light therapy

Traditional Chinese Medicine, Western Medicine and Low-level Light Therapy（LLLT） for Primary Dysmenorrhea（PD）

Start: Jun 2019Est. completion: Jun 2020480 patients
Phase 4Unknown
NCT05640232EMSCDE100 association

Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea

Start: Jun 2025Est. completion: Jan 2027238 patients
Phase 3Recruiting
NCT06268054EMSDEH113

Efficacy and Safety of DEH113 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea

Start: Feb 2025Est. completion: Sep 202778 patients
Phase 3Not Yet Recruiting
NCT04541134Daewon PharmaPelubiprofen 45mg

Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea

Start: Sep 2020Est. completion: Aug 2021120 patients
Phase 3Unknown
NCT00909857BayerEstradiol valerate, Dienogest

Effect on Primary Dysmenorrhea

Start: Apr 2009Est. completion: Nov 2010507 patients
Phase 3Completed
NCT00569244BayerDrug: YAZ flex

SH T00186 in the Treatment of Primary Dysmenorrhea

Start: Dec 2007Est. completion: Dec 2009223 patients
Phase 3Completed
NCT06555549EMSDEH113

Efficacy and Safety of DEH113 in the Treatment of Menstrual Cramp Pain in Primary Dysmenorrhea: a Pilot Study

Start: Sep 2024Est. completion: Feb 202660 patients
N/ANot Yet Recruiting
NCT04685343Human BioSciencesQuantitative Sensory Testing

Behavioral and Neural Phenotypes of Primary Dysmenorrhea in Adolescents

Start: Dec 2020Est. completion: Dec 2025164 patients
N/ACompleted
NCT04662814MTIshock wave therapy

Extracorporeal Shock Wave Therapy for Dysmenorrhea

Start: Sep 2020Est. completion: Jan 202150 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,920 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.